[Immune manipulation of BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukemia].
1. BCG (1 mg/mouse) administered i.v. on day 5 after chemotherapy by cyclophosphamide (CPM), given itself at the dose of 80 or 134 or 403 mg/kg one day after the inoculation of L 1210 leukaemia 10(3) cells, increases the effect of the non-optimal doses: i.e. 80 mg/kg, which is insufficient to cure mice, and 403 mg/kg, which is toxic. It does not change the effect of the optimal dose of CPM (134 mg/kg) which cures most of the mice. 2. BCG (1 mg/mouse i.v.) given on day 15 before CPM decreases the effect of the latter at the dose of 134 mg/kg. These results suggest that: a. BCG given after chemotherapy is not only able to eradicate the residual disease, but can decrease chemotherapy toxicity; b BCG given before an optimal dose of chemotherapy may decrease its antileukaemic effect, via the enhancement of the chemotherapy immunodepressive action, as demonstrated by skin graft experiments; this deterioration of the effect of chemotherapy by immunodepression was also suggested when the combination of CPM and antithymocyte serum was used.
D000818:Animals; D001500:BCG Vaccine; D003520:Cyclophosphamide / Q000627:therapeutic use*; D007167:Immunotherapy; D007939:Leukemia L1210 / Q000628:therapy*; D051379:Mice; D009163:Mycobacterium bovis / Q000276:immunology*; D013997:Time Factors
D001500:BCG Vaccine; D003520:Cyclophosphamide
Manipulation immunitaire par le BCG administré avant ou après la cyclophosphamide pour la chimio-immunothérapie de la leucémie L 1210